SUTRO BIOPHARMA, INC.
STRO evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for STRO—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · STRO
Sutro Biopharma is a clinical-stage biotechnology company developing antibody-drug conjugates (ADCs) and other protein-based therapeutics for oncology, leveraging its proprietary XpressCF and XpressCF+ platforms, with a strategic pivot from late-stage luvelta to preclinical assets.
Key risk: Cash runway uncertainty
BioSniper Score
Based on 4 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 6 pipeline candidates · 6 clinical trials for SUTRO BIOPHARMA, INC..
Sutro Biopharma is a clinical-stage biotechnology company developing antibody-drug conjugates (ADCs) and other protein-based therapeutics for oncology, leveraging its proprietary XpressCF and XpressCF+ platforms, with a strategic pivot from late-stage luvelta to preclinical assets.
- Sutro Biopharma is focused on developing antibody-drug conjugates (ADCs) for solid tumors using its XpressCF and XpressCF+ platforms [sec · filed 2026-04-22].
- In 2025, the company executed a strategic pivot from luvelta development to refocus on its preclinical portfolio [sec · filed 2026-04-22].
- The company filed an IND for STRO-004 ahead of schedule and nominated STRO-006 as a development candidate in the first half of 2025 [sec · filed 2026-04-22].
- As of June 30, 2026, Sutro reported cash & equivalents of $55.2M, total revenue of $9.8M, and a net loss of -$38.5M [sec].
- Sutro has multiple collaboration agreements with partners including BMS, Merck, Astellas, and Ipsen to support its operations [sec_mda · as of 2026-05-14].
What works
- Sutro's proprietary XpressCF and XpressCF+ platforms enable rapid and efficient development of ADCs and other protein therapeutics, supporting a robust preclinical pipeline [sec · filed 2024-04-26].
- The company has established multiple high-value collaborations with leading oncology partners (BMS, Merck, Astellas, Ipsen), providing non-dilutive funding and validation [sec_mda · as of 2026-05-14].
- Sutro successfully filed an IND for STRO-004 ahead of schedule and nominated STRO-006 as a development candidate, demonstrating preclinical execution capability [sec · filed 2026-04-22].
- The strategic pivot from luvelta to preclinical assets was executed efficiently, allowing the company to focus resources on earlier-stage, potentially higher-value programs [sec · filed 2026-04-22].
What to weigh
- Sutro has a history of net losses and negative shareholders' equity (-$32.1M as of June 30, 2026), indicating ongoing financial challenges [sec].
- The company will require additional financing to advance its product candidates into and through clinical development, and its current cash runway may not be sufficient beyond the next twelve months [sec_mda · as of 2026-08-12].
- Sutro's strategic pivot away from luvelta, a late-stage asset, introduces uncertainty as the company now relies on preclinical candidates with no clinical proof-of-concept yet [sec · filed 2026-04-22].
- The company faces significant competition in the ADC space from larger, well-capitalized biopharma firms, which could limit market opportunities for its pipeline [sec_mda · as of 2026-03-23].
From the filings
Quoted directly from source documents.
Sutro executed a strategic pivot from luvelta to preclinical portfolio in 2025.
“Efficiently executed a strategic pivot from luvelta development to refocus on our preclinical portfolio”
SEC filings · April 22, 2026
Sutro will need additional financing to advance its pipeline.
“We will continue to require additional financing to advance our current product candidates into and through clinical development”
SEC MD&A · August 12, 2026
Risks & what to watch (4)›
Key risks
- Cash runway uncertainty — Sutro's cash of $55.2M may not fund operations beyond 12 months; additional financing needed [sec_mda · as of 2026-08-12].
- Preclinical pipeline risk
- Competitive ADC landscape — Intense competition from larger biopharma firms could limit Sutro's market share [sec_mda · as of 2026-03-23].
- Negative shareholders' equity — Shareholders' equity of -$32.1M as of June 30, 2026, indicates financial distress [sec].
What to watch
- Progress of STRO-004 and STRO-006 through IND and into clinical trials [sec · filed 2026-04-22].
- Ability to secure additional financing through equity offerings, debt, or collaborations [sec_mda · as of 2026-08-12].
- Updates on partnered programs with BMS, Merck, Astellas, and Ipsen [sec_mda · as of 2026-05-14].
- Any clinical data readouts from preclinical candidates or partnered assets [sec · filed 2026-04-22].
Sources: SEC filings · SEC MD&A · Generated August 29, 2026 · How we verify sources →
Run SUTRO BIOPHARMA, INC. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available SUTRO BIOPHARMA, INC. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
12.8 months
OCF -$38M · Net income -$39M
Lead: Phase 2
6 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
69
Total value held
$352.8M
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 1,440,884 | $35.9M |
| perceptive advisors llc | 1,430,614 | $35.6M |
| bvf inc/il | 1,251,788 | $31.2M |
| affinity asset advisors, llc | 1,069,519 | $26.6M |
| samsara biocapital, llc | 1,062,872 | $26.5M |
| woodline partners lp | 914,882 | $22.8M |
| orbimed advisors llc | 801,144 | $20.0M |
| ra capital management, l.p. | 715,307 | $17.8M |
| eventide asset management, llc | 715,307 | $17.8M |
| adar1 capital management, llc | 524,441 | $13.1M |
Showing top 10 of 69 institutional holders of SUTRO BIOPHARMA, INC.. Open the full 13F history after sign-in.
Short Interest
as of Apr 19, 2026- % of float
- 3.9%
- Days to cover
- 3.1
- Shares short
- 639,714
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
STRO short interestGovernance
Frequently asked questions
What is the AI investment thesis for SUTRO BIOPHARMA, INC.?
Sutro Biopharma is a clinical-stage biotechnology company developing antibody-drug conjugates (ADCs) and other protein-based therapeutics for oncology, leveraging its proprietary XpressCF and XpressCF+ platforms, with a strategic pivot from late-stage luvelta to preclinical assets.
What is SUTRO BIOPHARMA, INC.'s lead drug candidate?
SUTRO BIOPHARMA, INC.'s most advanced tracked candidate is STRO-001 (Phase 1) for Ovarian Cancer.
Who is the CEO of SUTRO BIOPHARMA, INC.?
Ms. Jane Chung R.Ph. is the chief executive officer of SUTRO BIOPHARMA, INC. (STRO).
Where is SUTRO BIOPHARMA, INC. headquartered?
SUTRO BIOPHARMA, INC. (STRO) is headquartered in South San Francisco, CA, United States.
What therapeutic areas does SUTRO BIOPHARMA, INC. focus on?
SUTRO BIOPHARMA, INC. develops therapies across Oncology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.